Your browser doesn't support javascript.
loading
Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease.
Paraskevas, Kosmas I; Gloviczki, Peter; Antignani, Pier Luigi; Comerota, Anthony J; Dardik, Alan; Davies, Alun H; Eckstein, Hans-Henning; Faggioli, Gianluca; Fernandes E Fernandes, Jose; Fraedrich, Gustav; Geroulakos, George; Golledge, Jonathan; Gupta, Ajay; Gurevich, Victor S; Jawien, Arkadiusz; Jezovnik, Mateja K; Kakkos, Stavros K; Knoflach, Michael; Lanza, Gaetano; Liapis, Christos D; Loftus, Ian M; Mansilha, Armando; Nicolaides, Andrew N; Pini, Rodolfo; Poredos, Pavel; Proczka, Robert M; Ricco, Jean-Baptiste; Rundek, Tatjana; Saba, Luca; Schlachetzki, Felix; Silvestrini, Mauro; Spinelli, Francesco; Stilo, Francesco; Suri, Jasjit S; Svetlikov, Alexei V; Zeebregts, Clark J; Chaturvedi, Seemant; Veith, Frank J; Mikhailidis, Dimitri P.
Afiliação
  • Paraskevas KI; Department of Vascular Surgery, Central Clinic of Athens, Athens, Greece. Electronic address: paraskevask@hotmail.com.
  • Gloviczki P; Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN, USA.
  • Antignani PL; Vascular Centre, Nuova Villa Claudia, Rome, Italy.
  • Comerota AJ; Inova Heart and Vascular Institute, Inova Alexandria Hospital, Alexandria, VA, USA.
  • Dardik A; Division of Vascular and Endovascular Surgery, Yale University School of Medicine, New Haven, CT, USA.
  • Davies AH; Section of Vascular Surgery, Imperial College & Imperial Healthcare NHS Trust, London, UK.
  • Eckstein HH; Department for Vascular and Endovascular Surgery, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
  • Faggioli G; Vascular Surgery, University of Bologna "Alma Mater Studiorum", Policlinico S. Orsola Malpighi, Bologna, Italy.
  • Fernandes E Fernandes J; Department of Vascular Surgery, University of Lisbon, Lisbon Academic Medical Center, Lisbon, Portugal.
  • Fraedrich G; Department of Vascular Surgery, Medical University of Innsbruck, Innsbruck, Austria.
  • Geroulakos G; Department of Vascular Surgery, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Golledge J; Queensland Research Centre for Peripheral Vascular Disease, James Cook University and Townsville University Hospital, Townsville, Queensland, Australia.
  • Gupta A; Department of Radiology, Weill Cornell Medicine, New York, NY, USA.
  • Gurevich VS; Center of Atherosclerosis and Lipid Disorders, Saint-Petersburgh State University, North-Western State Medical University n.a. I.I. Mechnikov, St. Petersburgh, Russia.
  • Jawien A; Department for Vascular Surgery and Angiology, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
  • Jezovnik MK; Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Centre at Houston, Houston, TX, USA.
  • Kakkos SK; Department of Vascular Surgery, University of Patras Medical School, Patras, Greece.
  • Knoflach M; Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • Lanza G; Vascular Surgery Department, IRCSS MultiMedica Hospital, Castellanza, Italy.
  • Liapis CD; Athens Vascular Research Center, Athens, Greece.
  • Loftus IM; St. George's Vascular Institute, St. George's University London, London, UK.
  • Mansilha A; Faculty of Medicine of the University of Porto, Porto, Portugal; Department of Angiology and Vascular Surgery, Hospital de S. Joao, Porto, Portugal.
  • Nicolaides AN; Department of Surgery, University of Nicosia Medical School, Nicosia, Cyprus.
  • Pini R; Vascular Surgery, University of Bologna "Alma Mater Studiorum", Policlinico S. Orsola Malpighi, Bologna, Italy.
  • Poredos P; Department of Vascular Disease, University Medical Centre Ljubljana, Slovenia.
  • Proczka RM; 1(st) Department of Vascular Surgery, Medicover Hospital, Warsaw, Poland.
  • Ricco JB; Department of Clinical Research, University of Poitiers, CHU de Poitiers, Poitiers, France.
  • Rundek T; Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA.
  • Saba L; Department of Radiology, Azienda Ospedaliera Universitaria Di Cagliari, Cagliari, Italy.
  • Schlachetzki F; Department of Neurology, Center for Vascular Neurology and Intensive Care, University of Regensburg, Regensburg, Germany.
  • Silvestrini M; Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy.
  • Spinelli F; Vascular Surgery Division, Campus Bio-Medico University of Rome, Rome, Italy.
  • Stilo F; Vascular Surgery Division, Campus Bio-Medico University of Rome, Rome, Italy.
  • Suri JS; Stroke Diagnostic and Monitoring Division, Atheropoint™, Roseville, CA, USA.
  • Svetlikov AV; Division of Vascular and Endovascular Surgery, North-Western Scientific Clinical Center of Federal Medical Biological Agency of Russia, St. Petersburgh, Russia.
  • Zeebregts CJ; Division of Vascular Surgery, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Chaturvedi S; Department of Neurology & Stroke Program, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Veith FJ; Division of Vascular Surgery, New York University Langone Medical Center, New York, NY, USA; Division of Vascular Surgery, Cleveland Clinic, Cleveland, OH, USA.
  • Mikhailidis DP; Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London, UK.
Prog Cardiovasc Dis ; 73: 41-47, 2022.
Article em En | MEDLINE | ID: mdl-35605696
ABSTRACT
International guidelines strongly recommend statins alone or in combination with other lipid-lowering agents to lower low-density lipoprotein cholesterol (LDL-C) levels for patients with asymptomatic/symptomatic carotid stenosis (AsxCS/SCS). Lowering LDL-C levels is associated with significant reductions in transient ischemic attack, stroke, cardiovascular (CV) event and death rates. The aim of this multi-disciplinary overview is to summarize the benefits and risks associated with lowering LDL-C with statins or non-statin medications for Asx/SCS patients. The cerebrovascular and CV beneficial effects associated with statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and other non-statin lipid-lowering agents (e.g. fibrates, ezetimibe) are reviewed. The use of statins and PCSK9 inhibitors is associated with several beneficial effects for Asx/SCS patients, including carotid plaque stabilization and reduction of stroke rates. Ezetimibe and fibrates are associated with smaller reductions in stroke rates. The side-effects resulting from statin and PCSK9 inhibitor use are also highlighted. The benefits associated with lowering LDL-C with statins or non-statin lipid lowering agents (e.g. PCSK9 inhibitors) outweigh the risks and potential side-effects. Irrespective of their LDL-C levels, all Asx/SCS patients should receive high-dose statin treatment±ezetimibe or PCSK9 inhibitors for reduction not only of LDL-C levels, but also of stroke, cardiovascular mortality and coronary event rates.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Doenças das Artérias Carótidas / Inibidores de Hidroximetilglutaril-CoA Redutases / Acidente Vascular Cerebral / Anticolesterolemiantes Tipo de estudo: Diagnostic_studies / Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Doenças das Artérias Carótidas / Inibidores de Hidroximetilglutaril-CoA Redutases / Acidente Vascular Cerebral / Anticolesterolemiantes Tipo de estudo: Diagnostic_studies / Guideline Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article